CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...

As the NMPA joins the EU and the U.S. in placing sterility assurance and contamination control front and center, ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...